Hyperinfection with strongyloides stercolis occurs in the setting of chronic strongyloides infection in conjunction with immune suppression. Although malnutrition remains the major secondary cause worldwide in the developed world, iatrogenic immue suppression is an important precipitant. Autologous stem cell transplantation recipients are significantly immunocompromised albeit temporarily. Despite the increasing use of haemopoetic stem cell transplantation, hyperinfection with strongyloides has rarely been reported. We describe two cases of patients transplanted with chronic strongyloidiasis. In one case eradication therapy was given prior to the transplant which was uncomplicated. In the second case strongyloidiasis was diagnosed post transplant which was complicated by infection and respiratory compromise. Fatal hyperinfection subsequently developed after corticosteroid therapy was started for a disease progression in the CNS.
transplantation; myeloma; lymphoma Human strongyloidiasis is endemic throughout much of Africa, Asia, South America and the South Eastern United States. Primary infection involves penetration of the skin by soil-dwelling infectious filariform larvae. The ability of the excreted rhabditiform larvae to develop directly to the filariform without the need for an intermediate host allows the development of an auto-infection cycle and hence the capacity to maintain a lifelong infestation. This distinguishes Strongyloides from the other intestinal nematodes. We present here two patients with chronic strongyloidiasis who underwent autologous bone marrow transplantation, one of whom subsequently developed fatal hyperinfection.
Case 1
A 67-year-old Guyanian man who had been resident in the UK for the previous 36 years presented with IgG kappa myeloma in February 1998. He was treated to a partial response (PR) with three courses of VAD chemotherapy (infusional vincristine and doxorubicin with dexamethasone 40 mg D 1-5). Peripheral blood stem cells (PBSC) were subsequently mobilised with cyclophosphamide 1.5 g/m 2 and G-CSF. Prior to autograft in July 1998, the patient complained of epigastric discomfort for the previous 6 weeks. There were no associated gastrointestinal symptoms. An eosinophilia of 2.74 Â 10 9 /l was noted. His travel history was unremarkable, having last visited Guyana in 1976. Past medical history included falciparum malaria and duodenal ulcer treated with a proton pump inhibitor in 1995. Gastroscopy demonstrated a moderate erosive duodenitis but no parasites were seen on the duodenal aspirate. Strongyloides serology was strongly positive and Strongyloides stercoralis larvae were identified on direct microscopy of stool specimens using an ether concentration technique. The patient was treated with albendazole 400 mg b.i.d. for 3 days and ivermectin 200 mg/kg daily for 2 days. Since complete eradication of Strongyloides infection is difficult to prove, the treatment was repeated 1 week later. All subsequent stool examinations were negative. He had an uneventful autologous transplant conditioned with highdose melphalan (110 g/m 
Case 2
A 57-year-old man with a prior history of pulmonary tuberculosis presented in 1983 in India with a pathological fracture of his right humerus due to a diffuse large B-cell lymphoma. He received bleomycin, steroid and radiotherapy to a complete response (CR). In 1984, he moved to London. He subsequently remained well until 1996 when he represented with a biopsy-proven recurrent diffuse large B-cell lymphoma in a cervical lymph node. Bone marrow examination at that time revealed evidence of an underlying indolent lymphoma. He received six cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) with prophylactic intrathecal methotrexate to a CR. A third recurrence in 1999 was treated with three cycles of dexamethasone, cytarabine and cisplatin (DHAP) to a PR. After mobilisation of PBSC with etoposide, high-dose therapy with autologous stem cell rescue was undertaken in July 1999. The conditioning regimen included lomustine, cytarabine, cyclophosphamide and etoposide. Persistent fever and progressive respiratory deterioration complicated his post transplant course. He required intubation and assisted ventilation for a total of 13 days. On day 19 post transplant, a Gram-positive rod was isolated which was subsequently identified as an atypical mycobacterium (Mycobacterium chelonae). His third remission lasted until July 2000 when he had radiotherapy for a parotid relapse. In November 2000, he represented with a right parietal mass with substantial mass effect. The clinical diagnosis of recurrent lymphoma was made and dexamethasone was started. He went on to receive cranial radiotherapy. As the steroid dose was being reduced, he became unwell with rising inflammatory markers but no fever. Despite broad-spectrum antibiotics (including therapy for Pneumocystis) his chest radiograph deteriorated and he developed a cough and hypoxaemia. S. stercoralis was identified on bronchoalveolar lavage (Figure 1 ) and ivermectin and albendazole were added. Although blood cultures were subsequently sterile, and despite the subsequent addition of antifungal antibiotics his condition deteriorated, with clinical evidence of infection, and he died 44 days after the initiation of the steroids. An autopsy was not performed at the relatives' request.
Discussion
Strongyloidiasis is considered to be a disease of the tropics; however, the prevalence is also high in eastern Europe, the Italian Po valley and the south eastern USA. 1 The ability to develop directly into the infective filariform larvae allows an auto-infective cycle to become established and the potential for lifelong infection. Many human infections are asymptomatic. The commonest clinical manifestations of chronic disease are abdominal discomfort, often epigastric, and diarrhoea. Strongyloides hyperinfection occurs in the setting of immune suppression. [2] [3] [4] [5] The secondary infection due to the failure of intestinal mucosal integrity is a serious complication. In addition to the direct consequences of massive larval migration in tissues, penetration of larvae through the gut provides a portal of entry for Gramnegative organisms and this secondary infection is a major cause of death.
The widespread use of immunosuppressive drugs and the chronicity of strongyloidiasis makes hyperinfection a clinically important problem in nonendemic countries. However, all immunocompromised states do not seem to carry equal risk. It is notable that despite the overlap in endemic regions for both HIV and strongyloidiasis, the incidence of infection is not increased above that of the non-HIV-infected population. Furthermore, hyperinfection has been reported in association with HIV infection on only a handful of occasions. 6 There are no data on confirmed strongyloidiasis in the setting of bone marrow transplantation and little data post solid organ transplants. Renal allografts have been reported to precipitate hyperinfection although the majority are prior to 1990 and the immunosuppression in all cases was steroid based. 4 There are no reports of clinical strongyloidiasis in patients while immunosuppressed with cyclosporin, although there is one case where auto infection occurred in a patient receiving tacrolimus 7 and one case where hyperinfection occurred shortly after discontinuing cyclosporin. 8 Relevant to this is the observation that cyclosporin has antihelminth activity. 9, 10 We present here two patients who underwent autologous transplantation who had had chronic strongyloidiasis throughout their initial chemotherapy, which in both cases included corticosteroid. In the first case, Strongyloides was eradicated prior to the transplant and the patient had an uneventful transplant course. In the second case, the diagnosis was missed as the patient did not have an elevated eosinophil count (probably due to prior corticosteroid) and was asymptomatic. Although Strongyloides was not isolated, it is possible that it contributed to the severe infective complications. Subsequently, steroid alone was sufficient to allow fatal Strongyloides hyperinfection to develop. Steroid induced eosinopenia may be important. Eosinophils are known to be an important component of the immune response to Strongyloides infection. Activated eosinophils can undoubtedly kill helminthic parasites in vitro and IL5 knockout CB57BL/6 mice are more susceptible to primary Strongyloides infection. Likewise, eosinophils and IL5 are important in protective immunity in immunised mice although the number of eosinophils required may be small. 11, 12 Given the risks of strongyloidiasis in this immunocompromised patient population and the availability of effective therapy, the benefits of screening may seem obvious. The choice of investigations is less clear. Eosinophilia or elevation of IgE have sensitivities of up to 80 and 50%, respectively; however this does not apply to immunocompromised individuals where the sensitivities are much reduced (eosinophilia o20%). Direct identification of Strongyloides larvae provides the only definitive diagnosis. Multiple stool samples need to be examined to exclude the diagnosis. In chronic strongyloidiasis examination of 43 stool samples has a sensitivity of 60-70% and this may be higher in the immunocompromised. 13 The ether separation and Baermann concentration technique or stool culture for Strongyloides may be used to improve detection in stool. In the respiratory tract, diagnosis of strongyloidiasis on cytologic samples is only an occasional finding in the setting of hyperinfection. 14, 15 A Strongyloides ELISA test has a positive predictive value of 91% and a negative predictive value of 98% when used in a population with a prevalence of 10%, 16 making it a good screening test in patients from endemic regions. Detection of Strongyloides IgG does not discriminate between current and previous infection and thus the consequent lack of specificity is a problem in patients from endemic areas.
A major issue in nonendemic areas is when to screen. Given the association between steroid use and hyperinfection, it is as logical to screen patients prior to high-dose steroid therapy rather than restricting screening to pre transplant. Indeed in the setting of allogeneic transplant, the real risk period may not be the immediate peritransplant period but post transplant when graft-versus-host disease develops and cyclosporin is discontinued and corticosteroid started. Screening studies in patients with haematological malignancy in endemic regions suggest that chronic strongyloidiasis occurs in 8-20% of patients, even so reports of hyperinfection are uncommon in this population. 17 Chronic strongyloidiasis is a potential complicating factor of bone marrow transplantation, which may impact adversely on morbidity and mortality. It is a complication that is not restricted to the immediate peritransplant period. Patients with haematological malignancy receiving treatments other than bone marrow transplantation are at risk. The value of screening for strongyloidiasis is unclear but may be of benefit in patients from areas of high endemnicity. Ultimately, it is awareness of and vigilance for strongyloidiasis as a potential complication of immunosuppression including corticosteroid use that will reduce the morbidity and mortality from this infection.
